In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Micromet, Inc.

http://www.micromet.de

Latest From Micromet, Inc.

Beam And Verve Benefit From Buzz Around Base-Editing Therapies

Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.

Companies Commercial

Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko

Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.

Business Strategies Research and Development Strategies

Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds

Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns. 

Financing StartUps and SMEs

EU Approvals Beckon For Inrebic & Novel Adalimumab Biosimilar

Inrebic, Celgene’s myelofibrosis treatment, and Yuflyma, Celltrion’s high-concentration adalimumab biosimilar, are among the latest new drugs that have been recommended for approval for use across the EU. Meanwhile, TETEC has withdrawn its EU marketing application for Artobend.

Europe Approvals
See All

Company Information

  • Other Names / Subsidiaries
    • CancerVax Corporation
UsernamePublicRestriction

Register